Why Biomarker-Guided Radiotherapy in Breast Cancer Isn’t Ready for Prime TimeWhy Biomarker-Guided Radiotherapy in Breast Cancer Isn’t Ready for Prime Time
(MedPage Today) — A narrative review published earlier this year in JAMA Oncology highlighted a major gap in breast cancer care: While genomic tools guide systemic therapy, no clinically validated biomarker yet exists to inform radiotherapy decisions…
Tirzepatide may only temporarily suppress brain ‘food noise’ activityTirzepatide may only temporarily suppress brain ‘food noise’ activity
A rare glimpse into the brain activity of a patient with obesity and loss of control eating on tirzepatide, marketed as Mounjaro and Zepbound, revealed that the medication suppresses signaling in the brain’s “reward center” thought to be involved in food noise—but only temporarily. A rare glimpse into the brain activity of a patient with Read More
Single-dose radiation before surgery can eradicate breast cancerSingle-dose radiation before surgery can eradicate breast cancer
A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a study led by UT Southwestern Medical Center researchers. The findings, published in JAMA Network Open, could shift the paradigm for patients with the most common form of breast cancer, who typically undergo surgery before a regimen of radiation therapy.
Precision therapy could stop breast cancer at the sourcePrecision therapy could stop breast cancer at the source
Researchers at the University of California San Diego School of Medicine have identified a promising new therapy for triple-negative breast cancer (TNBC), which is among the most aggressive and difficult-to-treat forms of the disease.
STAT+: Pharmalittle: We’re reading about Novo plans for Wegovy, a Purdue bankruptcy deal, and moreSTAT+: Pharmalittle: We’re reading about Novo plans for Wegovy, a Purdue bankruptcy deal, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and messages has returned. But what can you do? There is no pause button to stop the world from spinning. So this means one thing: time to dig in to Read More
Novo Nordisk slashes out-of-pocket prices for Wegovy and OzempicNovo Nordisk slashes out-of-pocket prices for Wegovy and Ozempic
The Danish drugmaker said it’s cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the drugs directly. The Danish drugmaker said it’s cutting the price of Wegovy and Ozempic from $499 to $349 per month for some customers who buy the drugs directly.
GLP-1 drugs like Ozempic deliver huge weight loss but new research reveals a hidden catchGLP-1 drugs like Ozempic deliver huge weight loss but new research reveals a hidden catch
GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term safety, side effects, and global accessibility. Researchers stress the need for independent studies before these treatments can be fully embraced worldwide. GLP-1 drugs like tirzepatide and semaglutide offer powerful weight-loss effects but come with unanswered questions about long-term Read More
Study on breast cancer and birth control shows how science can be distortedStudy on breast cancer and birth control shows how science can be distorted
The study sought to answer questions about how breast cancer risk differs by type of hormonal contraceptive. Doctors say the results won’t change how they counsel patients.
New Guidance on Resmetirom and Semaglutide for MASHNew Guidance on Resmetirom and Semaglutide for MASH
(MedPage Today) — At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance on using resmetirom (Rezdiffra) and semaglutide (Ozempic, Wegovy) for metabolic dysfunction-associated steatohepatitis… (MedPage Today) — At the American Association for the Study of Liver Diseases (AASLD) annual meeting, a session highlighted new guidance Read More
GLP-1s Tied to Big Survival Advantage in Colon Cancer PatientsGLP-1s Tied to Big Survival Advantage in Colon Cancer Patients
(MedPage Today) — Patients with colon cancer and a history of treatment with GLP-1 receptor agonists for obesity had a 5-year mortality rate that was less than half the rate for patients who didn’t take these drugs, according to a large retrospective… (MedPage Today) — Patients with colon cancer and a history of treatment Read More